Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant tislelizumab monotherapy in urothelial carcinoma after radical surgery
ChiCTR2300068589Phase 2Recruiting
- Sponsor
- Beijing Hospital
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in transitional cell carcinoma (TCC), bladder cancer, upper tract urothelial carcinoma (UTUC) and 2 more, sponsored by Beijing Hospital. Primary endpoint: 1-year disease-free recurrence rate. Started Feb 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
transitional cell carcinoma (TCC)bladder cancerupper tract urothelial carcinoma (UTUC)Renal pelvis urothelial carcinoma (UTUC)ureteral cancer
Beyond the preview
Go deeper on ChiCTR2300068589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068589.